338 related articles for article (PubMed ID: 28537506)
1. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
Serrie A; Lange B; Steup A
Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials.
Lange B; Sohns M; Tempero J; Elling C
Curr Med Res Opin; 2018 Dec; 34(12):2113-2123. PubMed ID: 30200781
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
Biondi DM; Xiang J; Etropolski M; Moskovitz B
J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
[TBL] [Abstract][Full Text] [Related]
11. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
12. Tapentadol for chronic musculoskeletal pain in adults.
Santos J; Alarcão J; Fareleira F; Vaz-Carneiro A; Costa J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009923. PubMed ID: 26017279
[TBL] [Abstract][Full Text] [Related]
13. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
14. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
Thakur D; Dickerson S; Kumar Bhutani M; Junor R
Clin Ther; 2015 Jan; 37(1):212-24. PubMed ID: 25592091
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
[TBL] [Abstract][Full Text] [Related]
17. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
Coluzzi F; Ruggeri M
Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
